Coronary Artery Disease
Conditions
Brief summary
To evaluate the safety and effectiveness of computed tomography angiography in the diagnostic and therapeutic cycle as the first-choice method of imaging in the diagnosis of patients with a high probability of stable coronary artery disease according to European Society of Cardiology recommendations.
Detailed description
A prospective, randomized open-label, single center trial to evaluate superiority of angio-CT to a classic coronary angiography (concerning effectiveness and safety) in the diagnosis of stable coronary artery disease in patients with indications for invasive coronary angiography.
Interventions
Performation of non-invasive cardiac CT angiogram
Patient undergoes invasive coronary angiography
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age \>18 years 2. Patients providing written informed consent 3. Indications for elective invasive coronary angiography defined by European Society of Cardiology as: * Left ventricle ejection fraction \<50% and typical angina symptoms, * Probability of coronary artery disease due to criteria of age, sex and symptoms \>85%, or * Probability of coronary artery disease due to criteria of age, sex and symptoms 50-85% with positive or moderate cardiac stress test.
Exclusion criteria
1. No Consent to the study 2. Acute coronary syndrome 3. Recurrence of typical angina symptoms 1 year after the last percutaneous coronary revascularization, 4. Contraindications to invasive coronary angiography 5. GFR \<60 ml/min/1.73m2 6. Significant arrhythmia 7. BMI \>35 kg/m2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite outcome of: myocardial infarction, death, acute coronary syndrome, unplanned coronary revascularization, hospitalization for cardiovascular reason, stroke | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). |
| The proportion of avoidable invasive diagnostic procedures (coronary angiographies not followed by an intervention) in the arm: A. Angio-CT versus B. Classic diagnostics (superiority) | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). |
| The average number of invasive procedures (coronary angiography/PCI) in the arm: A. Angio - CT versus B. Classic diagnostics (superiority) | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of angioplasty procedures performed in accordance with ESC recommendations where the treatment planned on the basis of CT angiography by an interventional cardiologist is not treated ad-hoc. | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | — |
| Average number of therapeutic procedures (PCI/CABG). | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | — |
| Average consumption of resources (comparison of coronary artery disease diagnosis and treatment costs in accordance to National Health Service and Institute of Cardiology price lists. | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | — |
| Average number of days of hospitalization required to complete the diagnostic and therapeutic cycle. | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | — |
| Average time to complete diagnostic and therapeutic cycle (from the first examination of the coronary arteries to termination or disqualification from the surgical treatment). | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | — |
| composite outcome: number of serious adverse events during diagnosis and treatment of coronary artery disease | up to 36 months (through study completion) | composite of: - death, * acute coronary syndrome, * urgent hospitalization for cardiovascular causes, * stroke, * unplanned PCI as a treatment of invasive coronary angiography complications, * urgent CABG surgery as a result of PCI or coronary angiography complications, * surgical treatment of local vascular complications or with blood products, * hospitalization or prolongation of hospitalization due to local vascular complications, * the occurrence of a pseudoaneurysm, fistula, or occlusion in the vascular access site, * decrease in renal function (a fall of at least one stage of chronic kidney disease), * 2-5 type bleeding defined by Bleeding Academic Research Consortium, * life threat, need for hospitalization or its prolongation, durable or substantial health damage. |
| Time to occurrence of composite outcome of: myocardial infarction, death, acute coronary syndrome, unplanned coronary revascularization (including restenosis), urgent hospitalization for cardiovascular reason, stroke | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| The volume of contrast agent used for diagnosis and possible coronary intervention in the arm: A. Angio-CT versus B. Classic diagnostics (non-inferiority) | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | safety co-primary outcome |
| The radiation dose used for diagnosis of coronary artery disease and possible intervention in the arm: A. Angio-CT versus B. Classic diagnostics (non-inferiority) | up to 3 months (until the last diagnostic/therapeutic procedure; it is assumed it will be completed within 3 months of the participants study entry). | safety co-primary outcome |
Countries
Poland